- Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19
- Interim report January - March 2021: Vicore Pharma Holding AB
- Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF
- Vicore Pharma to host Key Opinion Leader webinar on C21 for the treatment of COVID-19
Vicore Pharma Holding AB (VICO:STO) closed at 24.20, 64.63% above the 52 week low of 14.70 set on Jun 23, 2020.
14.70Jun 23 202038.30Dec 28 2020
Markit short selling activity
|Market cap||1.74bn SEK|
|EPS (TTM)||-2.85 |
Data delayed at least 15 minutes, as of Jun 11 2021 17:00 BST.